This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Connolly, D. C. Articles by Cho, K. R. Search for Related Content PubMed PubMed Citation Articles by Connolly, D. C. Articles by Cho, K. R.

Loss of Fhit Expression in Invasive Cervical Carcinomas and Intraepithelial Lesions Associated with Invasive Disease¹

Departments of Pathology and Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan 48109 [D. C. C., R. W., X. R., K. R. C.]; Biostatistics Core, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 [R. L. D.]; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [D. L. G.]; Department of Microbiology and Immunology, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205 [K. V. S.]; National Women’s Hospital, Epsom, Auckland, New Zealand [R. W. J.]; Servei D’Epidemiologia I Registre Del Cancer, Institut Catala D’Oncologia, E-08907 L’Hospitalet Del Llobregat, Barcelona, Spain [F. X. B.]; and IARC, 69372 Lyon, Cedex 08, France [N. M.]

Allelic losses involving chromosome 3p are frequently observed in cervical cancers. Deletion mapping studies of primary cervical carcinomas have localized common regions of deletion to 3p14.2 and 3p21. The candidate tumor suppressor gene FHIT has been mapped to 3p14.2, and previous studies have demonstrated reduced or aberrant FHIT transcripts and reduced or absent Fhit protein expression in a large percentage of cervical cancer-derived cell lines and primary cervical carcinomas. To expand these observations to preinvasive cervical epithelial lesions and to determine whether loss of Fhit protein expression might be associated with tumor progression, immunohistochemical methods were used to examine Fhit expression in 95 invasive cervical carcinomas, 33 high-grade squamous intraepithelial lesions (HSILs) associated with concurrent invasive cancer, 38 HSILs unassociated with invasive cancer, 24 low-grade squamous intraepithelial lesions, and 22 normal cervix samples. All normal cervical epithelia and low-grade squamous intraepithelial lesions exhibited diffuse cytoplasmic immunostaining of moderate to strong intensity. Fhit protein expression was markedly reduced or absent in 67 of 95 (71%) invasive cancers, 17 of 33 (52%) HSILs associated with invasive cancer, and 8 of 38 (21%) HSILs without associated invasive cancer. The results confirm that Fhit protein expression is reduced or absent in the majority of cervical carcinomas and suggest that loss of Fhit expression often accompanies cervical tumor progression. Moreover, absent or reduced Fhit protein is observed at a significantly higher frequency in HSILs associated with progression to invasive cancer than in HSILs with unknown risk for progression (P = 0.012). These findings suggest that loss of Fhit expression in HSILs could serve as a useful marker of high-grade preinvasive lesions that have an increased likelihood of progression to invasive carcinoma.

This article has been cited by other articles:

				H. Zhang, Y.-J. Hou, S.-Y. Han, E. C. Zhang, K. Huebner, and J. Zhang Mammalian nitrilase 1 homologue Nit1 is a negative regulator in T cells Int. Immunol., June 1, 2009; 21(6): 691 - 703. [Abstract] [Full Text] [PDF]

				Y. Zhai, K. B. Hotary, B. Nan, F. X. Bosch, N. Munoz, S. J. Weiss, and K. R. Cho Expression of Membrane Type 1 Matrix Metalloproteinase Is Associated with Cervical Carcinoma Progression and Invasion Cancer Res., August 1, 2005; 65(15): 6543 - 6550. [Abstract] [Full Text] [PDF]

				L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines PNAS, March 19, 2002; 99(6): 3615 - 3620. [Abstract] [Full Text] [PDF]

				Q. Yang, G. Yoshimura, T. Suzuma, T. Tamaki, T. Umemura, M. Nakamura, Y. Nakamura, X. Wang, I. Mori, T. Sakurai, et al. Clinicopathological Significance of Fragile Histidine Triad Transcription Protein Expression in Breast Carcinoma Clin. Cancer Res., December 1, 2001; 7(12): 3869 - 3873. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 17, 2001; (2001) 191345898. [Abstract] [Full Text] [PDF]

				T. C. Krivak, J. W. McBroom, J. Seidman, D. Venzon, B. Crothers, P. J. MacKoul, G. S. Rose, J. W. Carlson, and M. J. Birrer Abnormal Fragile Histidine Triad (FHIT) Expression in Advanced Cervical Carcinoma: A Poor Prognostic Factor Cancer Res., June 1, 2001; 61(11): 4382 - 4385. [Abstract] [Full Text] [PDF]

				N. Zanesi, V. Fidanza, L. Y. Fong, R. Mancini, T. Druck, M. Valtieri, T. Rudiger, P. A. McCue, C. M. Croce, and K. Huebner The tumor spectrum in FHIT-deficient mice PNAS, August 28, 2001; 98(18): 10250 - 10255. [Abstract] [Full Text] [PDF]